Janssen Gains Traditional FDA Approval for Rybrevant in First-Line EGFR NSCLC

Janssen Biotech's conversion of amivantamab-vmjw (Rybrevant) from accelerated to traditional approval signals a tightening regulatory sequence that CMC and regulatory affairs teams should map against their own rolling-review timelines. On March 1, 2024, the FDA granted two distinct approvals: full traditional approval for the previously accelerated second-line indication in adult patients with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations whose disease progressed on or after platinum-based chemotherapy, and a new traditional approval for first-line use in combination with carboplatin and pemetrexed.

Efficacy for the first-line indication was established in PAPILLON (NCT04538664), a randomized, open-label, multicenter trial of 308 patients. Blinded independent central review assessed progression-free survival as the major efficacy outcome. Amivantamab-vmjw plus carboplatin and pemetrexed produced a median PFS of 11.4 months versus 6.7 months for chemotherapy alone, with a hazard ratio of 0.40 (95% CI: 0.30, 0.53; p<0.0001). Overall survival data remained immature at the time of analysis, with 44% of pre-specified events reported; no detrimental trend was observed.

The review architecture is as instructive as the clinical data. FDA processed this application through the Real-Time Oncology Review (RTOR) pilot, enabling rolling data submission ahead of the complete clinical filing, and accepted an Assessment Aid from Janssen to structure its evaluation. The application also ran concurrently under Project Orbis, with ANVISA and Health Canada as co-reviewing partners; those agency reviews remain ongoing. The net result: approval four weeks ahead of the FDA goal date under priority review designation.

For regulatory affairs leads managing oncology biologics, the Janssen submission illustrates how RTOR compresses the review clock without reducing CMC scrutiny. Teams preparing rolling submissions should anticipate that data packages supporting manufacturing comparability, container-closure integrity, and process validation must be submission-ready well before the complete clinical dossier is filed. Any lag in CMC readiness risks offsetting the timeline gains RTOR is designed to deliver.

The most common adverse reactions reported at a frequency of 20% or greater included rash, nail toxicity, stomatitis, infusion-related reaction, fatigue, and edema, among others; dosing is weight-based per the full prescribing information. Patient selection requires confirmation of EGFR exon 20 insertion mutations via an FDA-approved companion diagnostic test, a requirement that extends to site-level laboratory qualification and supply-chain readiness for the diagnostic.

With Project Orbis reviews still active at ANVISA and Health Canada, manufacturers supporting international launch should monitor alignment between agency-specific labeling outcomes and the approved US prescribing information as a near-term regulatory checkpoint.

Source: FDA Oncology Center of Excellence via FDA.gov Drugs RSS Feed, November 7, 2026.